“Role of Natalizumab in Relapsing-Remitting Multiple Sclerosis: A review”, J. Brain Spine Fdn Nep., vol. 2, no. 1, pp. 2–12, Aug. 2021, doi: 10.3126/jbsfn.v2i1.39000.